Royalty Pharma financials
$58.22−0.26%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B | $2.12B |
| Gross profit | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B | $2.12B |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $1.56B | $1.29B | $1.49B | $307.1M | $1.43B | $1.60B |
| Net income | $770.9M | $859.0M | $1.13B | $42.8M | $619.7M | $495.2M |
| Net margin | 32.4% | 37.9% | 48.2% | 1.9% | 27.1% | 23.3% |
| Diluted EPS | $1.78 | $1.91 | $2.53 | $0.10 | $1.49 | $1.32 |
| EBITDA | $1.56B | $1.29B | $1.49B | $1.83B | $1.91B | $1.91B |
| Operating cash flow | $2.49B | $2.77B | $2.99B | $2.14B | $2.02B | $2.03B |
| Free cash flow | $2.49B | $2.77B | $2.99B | $2.14B | $2.02B | — |
| Diluted shares | 564.5M | 594.1M | 602.9M | 438.0M | 414.8M | 375.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $618.7M | $929.0M | $477.0M | $1.71B | $1.54B | $1.01B |
| Short-term investments | $18.8M | $58.2M | $18.3M | $25.7M | $647.9M | $1.05B |
| Total debt | $9.06B | $7.71B | $6.19B | $7.17B | $7.15B | $5.86B |
| Total assets | $19.62B | $18.22B | $16.38B | $16.81B | $17.52B | $16.02B |
| Total liabilities | $9.91B | $7.88B | $6.30B | $7.29B | $7.27B | $6.12B |
| Shareholders' equity | $9.71B | $10.34B | $10.08B | $9.53B | $10.25B | $9.90B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology